Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BMJ Publishing Group
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070281/ |
| id |
pubmed-5070281 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-50702812016-11-14 Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study Gutzmer, R Rivoltini, L Levchenko, E Testori, A Utikal, J Ascierto, P A Demidov, L Grob, J J Ridolfi, R Schadendorf, D Queirolo, P Santoro, A Loquai, C Dreno, B Hauschild, A Schultz, E Lesimple, T P Vanhoutte, N Salaun, B Gillet, M Jarnjak, S De Sousa Alves, P M Louahed, J Brichard, V G Lehmann, F F Original Research BMJ Publishing Group 2016-08-08 /pmc/articles/PMC5070281/ /pubmed/27843625 http://dx.doi.org/10.1136/esmoopen-2016-000068 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Gutzmer, R Rivoltini, L Levchenko, E Testori, A Utikal, J Ascierto, P A Demidov, L Grob, J J Ridolfi, R Schadendorf, D Queirolo, P Santoro, A Loquai, C Dreno, B Hauschild, A Schultz, E Lesimple, T P Vanhoutte, N Salaun, B Gillet, M Jarnjak, S De Sousa Alves, P M Louahed, J Brichard, V G Lehmann, F F |
| spellingShingle |
Gutzmer, R Rivoltini, L Levchenko, E Testori, A Utikal, J Ascierto, P A Demidov, L Grob, J J Ridolfi, R Schadendorf, D Queirolo, P Santoro, A Loquai, C Dreno, B Hauschild, A Schultz, E Lesimple, T P Vanhoutte, N Salaun, B Gillet, M Jarnjak, S De Sousa Alves, P M Louahed, J Brichard, V G Lehmann, F F Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study |
| author_facet |
Gutzmer, R Rivoltini, L Levchenko, E Testori, A Utikal, J Ascierto, P A Demidov, L Grob, J J Ridolfi, R Schadendorf, D Queirolo, P Santoro, A Loquai, C Dreno, B Hauschild, A Schultz, E Lesimple, T P Vanhoutte, N Salaun, B Gillet, M Jarnjak, S De Sousa Alves, P M Louahed, J Brichard, V G Lehmann, F F |
| author_sort |
Gutzmer, R |
| title |
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study |
| title_short |
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study |
| title_full |
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study |
| title_fullStr |
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study |
| title_full_unstemmed |
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study |
| title_sort |
safety and immunogenicity of the prame cancer immunotherapeutic in metastatic melanoma: results of a phase i dose escalation study |
| description |
|
| publisher |
BMJ Publishing Group |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070281/ |
| _version_ |
1613689543752417280 |